Syndax Announces Positive Data for Revumenib in Patients with Acute Leukemias from the BEAT AML, SAVE AML and AUGMENT-102 Phase 1 Combination Trials

Data collectively highlight revumenib ' s combination potential with current standard of care agents and support advancement into pivotal combination trials in the frontline setting 100% CRc observed in BEAT AML trial exploring revumenib in...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials